Literature DB >> 26958638

Data on cell cycle in breast cancer cell line, MDA-MB-231 with ferulic acid treatment.

Eunmi Park1.   

Abstract

Inhibition to repair DNA metabolism to respond to damaged DNA can lead to genetic instability, resulting in cancer cell death (Audeh et al., 2010; Bryant et al., 2005; Farmer et al., 2005; Lukas et al., 2003; Tutt et al., 2010) [1], [2], [6], [8], [11]. Despite of various studies demonstrating efficiency of combination therapy through down-regulation of DNA repair pathway, the suppression effects of DNA repair pathway by chemotherapeutic agents from natural bioactive compounds are less understood (Eitsuka et al., 2014; Kastan et al., 2004; Kawabata et al., 2000; Mancuso et al., 2014) [5], [7], [9]. Here, the data shows that ferulic acid reduced the S-phases post to UV treatment in breast cancer cells and was hypersensitive in breast cancer cells, MDA-MB-231.

Entities:  

Year:  2016        PMID: 26958638      PMCID: PMC4764770          DOI: 10.1016/j.dib.2016.02.001

Source DB:  PubMed          Journal:  Data Brief        ISSN: 2352-3409


Specifications Table Value of the data The data significantly extends ferulic acid treatment in breast cancer chemotherapy. The data provides the information of the effect of different UV irradiations in breast cancer cells with ferulic acid treatment.

Data

FACS profiles showed that ferulic acid in combination with UV irradiation reduced more the S-phase compared to the cells treated with UV irradiation, as well as in UV untreated cells [3] (Fig. 1). MDA-MB-231 cells with ferulic acid were more sensitive to UV treatment compared to the cells with DMSO by performing colony formation assays [4] (See Fig. 2).
Fig. 1

Ferulic acid reduces S-phase cell cycle profiles post to UV treatment. MDA-MB-231 cells were cultured with 10 μM ferulic acid/or DMSO for 24 h. The cells were exposed to UV treatment and harvested. The cell pellets were fixed in 70% ethanol and stained with PI for FACS analysis. UV-; UV untreated, UV+; UV treated (20 mJ/s, harvest post to 3 h).

Fig. 2

Breast cancer cells with ferulic acid treatment are highly sensitive to UV treatment. MDA-MB-231 cells were pretreated with ferulic acid (10 μM) or DMSO for 24 h and re-plated in culture dishes. Then the cells were exposed with UV irradiation (0−20 mJ/s). Survival was determined using a colony assay from three independent experiments. The data are mean±standard errors. *; p<0.05.

Experimental design, materials and methods

Cell culture

MDA-MB-231 breast cancer cells were cultured in DMEM (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen) and 1% penicillin/streptomycin (Invitrogen) [3], [4]. The cells were cultured with ferulic acid (Sigma) treatment for experiments. Ferulic acid was dissolved in DMSO was dissolved in PBS for the experiments. All of cell lines were incubated at 37 °C with 5% CO2.

Cell cycle analysis

MDA-MB-231 breast cancer cells were pretreated with ferulic acid or DMSO for 24 h. The cells were exposed to 20 mJ/s UV treatment and harvested post to 3 h. For fluorescence-activated cell sorting (FACS) analysis, MDA-MB-231 cells were fixed overnight at 4C in 70% ethanol, stained with propidium iodine (PI) for 1 h. The cells analyzed for DNA content using a FACS Calibur machine (BD Biosciences).

Colony assay (Cell survival analysis)

MDA-MB-231 breast cancer cells were prepared for colony assay [10]. After the pre-treatments with ferulic acid or DMSO, the cells were plated in plates with UV irradiation (0−20 mJ/s). The cells were cultured for clonogenic assay in triplicates. After 2 weeks in culture, colonies were fixed with methanol and stained with crystal violet.

Statistical analysis

All data are representative of at least three independent experiments. Data are mean±SEM unless otherwise indicated. Statistical significance of comparison between two groups was determined by two-tailed Student׳s t-test where indicated. For comparing more than one group, one-way ANOVA was used. Significant differences were considered at p-values of less than 0.05.
Subject areaBiology
More specific subject areaCancer biology
Type of dataFigure, graph
How data was acquiredFACS analysis and colony assay
Data formatAnalyzed with FACS data, colony assay and statistical tests
Experimental factorsComparison of ferulic acid with UV-induced DNA damage in MDA-MB−231 cells
Experimental featuresCell cycle analysis and colony assay in breast cancer cell line, MDA-MB−231 with ferulic acid treatment post to UV.
Data source locationDaejeon, Korea
Data accessibilityData is within this article
  12 in total

Review 1.  Cell-cycle checkpoints and cancer.

Authors:  Michael B Kastan; Jiri Bartek
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

Review 2.  Ferulic acid: pharmacological and toxicological aspects.

Authors:  Cesare Mancuso; Rosaria Santangelo
Journal:  Food Chem Toxicol       Date:  2013-12-25       Impact factor: 6.023

3.  Inactivation of Uaf1 causes defective homologous recombination and early embryonic lethality in mice.

Authors:  Eunmi Park; Jung Min Kim; Benjamin Primack; David M Weinstock; Lisa A Moreau; Kalindi Parmar; Alan D D'Andrea
Journal:  Mol Cell Biol       Date:  2013-09-03       Impact factor: 4.272

4.  Curcumin enhances poly(ADP-ribose) polymerase inhibitor sensitivity to chemotherapy in breast cancer cells.

Authors:  Young Eun Choi; Eunmi Park
Journal:  J Nutr Biochem       Date:  2015-08-08       Impact factor: 6.048

5.  Modifying effects of ferulic acid on azoxymethane-induced colon carcinogenesis in F344 rats.

Authors:  K Kawabata; T Yamamoto; A Hara; M Shimizu; Y Yamada; K Matsunaga; T Tanaka; H Mori
Journal:  Cancer Lett       Date:  2000-08-31       Impact factor: 8.679

6.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

Authors:  Andrew Tutt; Mark Robson; Judy E Garber; Susan M Domchek; M William Audeh; Jeffrey N Weitzel; Michael Friedlander; Banu Arun; Niklas Loman; Rita K Schmutzler; Andrew Wardley; Gillian Mitchell; Helena Earl; Mark Wickens; James Carmichael
Journal:  Lancet       Date:  2010-07-06       Impact factor: 79.321

7.  Ferulic acid in combination with PARP inhibitor sensitizes breast cancer cells as chemotherapeutic strategy.

Authors:  Young Eun Choi; Eunmi Park
Journal:  Biochem Biophys Res Commun       Date:  2015-02-10       Impact factor: 3.575

8.  Synergistic inhibition of cancer cell proliferation with a combination of δ-tocotrienol and ferulic acid.

Authors:  Takahiro Eitsuka; Naoto Tatewaki; Hiroshi Nishida; Tadao Kurata; Kiyotaka Nakagawa; Teruo Miyazawa
Journal:  Biochem Biophys Res Commun       Date:  2014-10-05       Impact factor: 3.575

9.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.

Authors:  Helen E Bryant; Niklas Schultz; Huw D Thomas; Kayan M Parker; Dan Flower; Elena Lopez; Suzanne Kyle; Mark Meuth; Nicola J Curtin; Thomas Helleday
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504

10.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

Authors:  Hannah Farmer; Nuala McCabe; Christopher J Lord; Andrew N J Tutt; Damian A Johnson; Tobias B Richardson; Manuela Santarosa; Krystyna J Dillon; Ian Hickson; Charlotte Knights; Niall M B Martin; Stephen P Jackson; Graeme C M Smith; Alan Ashworth
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504

View more
  4 in total

1.  Combined Analysis of ChIP Sequencing and Gene Expression Dataset in Breast Cancer.

Authors:  Pengfei Liu; Wenhua Jiang; Shiyong Zhou; Jun Gao; Huilai Zhang
Journal:  Pathol Oncol Res       Date:  2016-09-21       Impact factor: 3.201

2.  Computer-aided drug design and inhibitive effect of a novel nitrogenous heterocyclic compound and its mechanism on glioma U251 cells and breast cancer MCF-7 cells.

Authors:  Liyu Qian; Yu Zhu
Journal:  Drug Des Devel Ther       Date:  2018-06-27       Impact factor: 4.162

3.  Statistical data analysis of cancer incidences in insurgency affected states in Nigeria.

Authors:  Patience I Adamu; Pelumi E Oguntunde; Hilary I Okagbue; Olasunmbo O Agboola
Journal:  Data Brief       Date:  2018-05-05

4.  Breast cancer patients in Nigeria: Data exploration approach.

Authors:  Pelumi E Oguntunde; Adebowale O Adejumo; Hilary I Okagbue
Journal:  Data Brief       Date:  2017-09-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.